| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/27/2001 | US20010025037 Introducing a patient in need of insulin into the lower respiratory tract an effective amount of active compounds in the form of powder containing insulin and bile salt which enhance the absorption of insulin in the lungs of patient |
| 09/27/2001 | US20010025035 Water soluble prodrugs of hindered alcohols |
| 09/27/2001 | US20010025031 HFGAN72 receptor genomic DNA, variants thereof, and methods of use thereof in diagnostic applications |
| 09/27/2001 | US20010025030 cDNA for human methylenetetrahydrofolate reductase and uses thereof |
| 09/27/2001 | US20010025027 Inhibition of ceramide for the prevention and treatment of oral mucositis induced by antineoplastic drugs or radiation |
| 09/27/2001 | US20010025026 Chimeric proteins for use in transport of a selected substance into cells |
| 09/27/2001 | US20010025025 Reacting cyclosporin with hexamethyldisilazane in prevence of a metal halide |
| 09/27/2001 | US20010025024 Administering botulinum toxin |
| 09/27/2001 | US20010025023 Inhibition of beta cell degeneration |
| 09/27/2001 | US20010025022 Hnovilr |
| 09/27/2001 | US20010024824 Stem cells and their use in transplantation |
| 09/27/2001 | US20010024823 Providing an osteogenic protein in a biocompatible bioresorbable carrier to defect locus, thereby inducing formation of functional replacement cartilage tissue |
| 09/27/2001 | US20010024817 Viral nucleotide sequences |
| 09/27/2001 | US20010024813 Human dendriac and brainiac-3 |
| 09/27/2001 | US20010024808 Leptin induced genes |
| 09/27/2001 | US20010024792 Method of detecting risk of type II diabetes based on mutations found in carboxypeptidase E |
| 09/27/2001 | US20010024786 Purified polypeptide of given sequence; useful in diagnosis, prevention, and treatment of cancer, inflammation, and disorders of fatty acid metabolism |
| 09/27/2001 | US20010024783 By administering a heat and RnaseH resistant antisense agent and detecting the presence in a body fluid sample of a nuclease-resistant heteroduplex of the antisense oligomer and the target RNA; detecting infective agents, pregnancy |
| 09/27/2001 | US20010024658 A delayed release pharmaceutical dosage form for oral administration of heparin comprising a low molecular weight heparin, a bile salt or acid, and a surfactant selected from hydrophilc and lipophilic, and a means for sustained release |
| 09/27/2001 | US20010024650 Artery - and vein-specific proteins and uses therefor |
| 09/27/2001 | US20010024648 Four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effeftive immunosuppressants for the treatment of autoimmune diseases and prevent organ trasplant rejection |
| 09/27/2001 | US20010024647 Single chain variable region immunoglobulin (ScFv) fragment antibody that binds selectively to the active conformation of human von Willebrand Factor (vWF) and the antibody inhibits the binding of vWF to platelets |
| 09/27/2001 | US20010024645 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| 09/27/2001 | DE10015413A1 Composition for treating and diagnosing viral infections, caused by adenovirus, comprises an agent that modifies function of YB-1 protein, and YB-1 specific antibodies |
| 09/27/2001 | DE10011530A1 New antisense oligonucleotides that inhibit polo-like kinase, useful for treating tumors that overexpress this kinase, have strong and selective action |
| 09/27/2001 | DE10006174A1 Isoform of neuregulin-beta with acidic isoelectric point, useful as indicator or target, e.g. in screening for potential neurological agents |
| 09/27/2001 | CA2689798A1 Talaromyces emersonii beta-glucanases |
| 09/27/2001 | CA2409643A1 Improvements in and relating to digestive/laxative compositions |
| 09/27/2001 | CA2406993A1 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex |
| 09/27/2001 | CA2404253A1 Novel ecdysone receptor-based inducible gene expression system |
| 09/27/2001 | CA2404226A1 Furoisoquinoline derivatives, process for producing the same and use thereof |
| 09/27/2001 | CA2404216A1 Novel polypeptides, and nucleic acids encoding the same |
| 09/27/2001 | CA2404139A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2404115A1 The use of peg-hirudin as an anticoagulant agent in the extracorporeal treatment of blood |
| 09/27/2001 | CA2404112A1 Sustained release delivery systems for solutes |
| 09/27/2001 | CA2404088A1 Bi-functional cancer treatment agents |
| 09/27/2001 | CA2404078A1 Immunokine composition and method |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403809A1 Angiogenesis - associated proteins, and nucleic acids encoding the same |
| 09/27/2001 | CA2403804A1 Vegf-modulated genes and methods employing them |
| 09/27/2001 | CA2403803A1 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid |
| 09/27/2001 | CA2403788A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | CA2403784A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2403714A1 Use of substances modulating the expression or the function of a protein involved in the cell cycle for treating or preventing acute neural injuries |
| 09/27/2001 | CA2403684A1 Therapeutic anti-melanoma compounds |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403631A1 Spiropiperidine derivatives as melanocortin receptor agonists |
| 09/27/2001 | CA2403572A1 Fibroblast growth factor receptor-like molecules and uses thereof |
| 09/27/2001 | CA2403486A1 Talaromyces emersonii beta-glucanases |
| 09/27/2001 | CA2403447A1 Peptide derivative |
| 09/27/2001 | CA2403444A1 Restenosis treatment |
| 09/27/2001 | CA2403434A1 Human gata-5 transcription factor |
| 09/27/2001 | CA2402834A1 Brca-1 regulators and methods of use |
| 09/27/2001 | CA2402816A1 Antisense nucleic acid molecules targeted to type i collagenase (mmp-1) for inhibition of melanoma invasion |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402757A1 Helical protein zalpha51 |
| 09/27/2001 | CA2402722A1 Sperm factor oscillogenin |
| 09/27/2001 | CA2402636A1 Composition and method for the prevention and/or the treatment of allergy |
| 09/27/2001 | CA2402414A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2402285A1 Nimr compositions and their methods of use |
| 09/27/2001 | CA2402252A1 Salmonella vaccine materials and methods |
| 09/27/2001 | CA2401984A1 Sulfur substituted aryldifluoromethylphosphonic acids as ptp-1b inhibitors |
| 09/27/2001 | CA2401749A1 Compounds and methods to treat alzheimer's disease |
| 09/27/2001 | CA2401067A1 Methods for screening and identifying pathogen virulence factors |
| 09/27/2001 | CA2400638A1 7 human ovarian and ovarian cancer associated proteins |
| 09/27/2001 | CA2399028A1 Use of mia in immunotherapy |
| 09/27/2001 | CA2389173A1 Agent for treating hepatitis c |
| 09/27/2001 | CA2383848A1 Diagnosis of a person's risk of developing alcoholism |
| 09/27/2001 | CA2374073A1 Novel polypeptides and nucleic acids encoding same |
| 09/26/2001 | EP1136561A2 Targeting gene therapy |
| 09/26/2001 | EP1136558A1 Genetically modified plants and plant cells comprising heterologous heavy metal transport and complexation proteins |
| 09/26/2001 | EP1136557A1 Proteins and polypeptides from Haemophilus influenzae involved in paracytosis, nucleotide sequences encoding them and uses thereof |
| 09/26/2001 | EP1136556A1 Multivalent antigen-binding proteins |
| 09/26/2001 | EP1136555A1 Novel tumor antigen protein art-1 and tumor antigen peptide thereof |
| 09/26/2001 | EP1136553A1 Production of recombinant blood clotting factors in human cell lines |
| 09/26/2001 | EP1136549A1 Dnas encoding novel polypeptides |
| 09/26/2001 | EP1136548A1 Novel trypsin family serine proteases |
| 09/26/2001 | EP1136547A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/26/2001 | EP1136500A2 Seroreactive regions from the HPV proteins E1 and E2 |
| 09/26/2001 | EP1136498A1 Inhibitors of serine proteases, particularly hepatitis c virus NS3 protease |
| 09/26/2001 | EP1136084A1 Compositions containing thrombin and process for their manufacture |
| 09/26/2001 | EP1136083A1 Gene therapy for cardiomyopathy |
| 09/26/2001 | EP1136080A2 Use of o-vanillin and o-vanillin/trolox combinations |
| 09/26/2001 | EP1136079A1 Agents for retarding change of hormone-dependent cancer into hormone-independent cancer |
| 09/26/2001 | EP1136078A2 Combination of angiotensin converting enzyme inhibitor and side- effect-reduced amount of aldosterone antagonist |
| 09/26/2001 | EP1136076A1 Method of increasing bone toughness and stiffness and reducing fractures |
| 09/26/2001 | EP1136075A1 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 09/26/2001 | EP1136071A2 Use of glycogen phosphorylase inhibitors |
| 09/26/2001 | EP1136068A2 Powder containing physiologically active peptide |
| 09/26/2001 | EP1135991A2 Oil composition and use thereof |
| 09/26/2001 | EP1135688A2 Methods and compositions useful for targeting activated vitronectin receptor alpha(nu)-beta(3) |
| 09/26/2001 | EP1135535A2 Development of anti-microbial agents based on bacteriophage genomics |
| 09/26/2001 | EP1135516A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 09/26/2001 | EP1135515A2 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 09/26/2001 | EP1135513A1 Adenovirus-mediated gene therapy |
| 09/26/2001 | EP1135505A1 Therapeutic agents comprising an e3 ubiquitin ligase for use in degenerative disorders |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135503A2 DRUG TARGETS IN $i(CANDIDA ALBICANS) |
| 09/26/2001 | EP1135501A1 Chlamydia antigens and corresponding dna fragments and uses thereof |